Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 4;21(6):184.
doi: 10.3892/br.2024.1872. eCollection 2024 Dec.

Involvement of everolimus‑induced ABCB1 downregulation in drug‑drug interactions

Affiliations

Involvement of everolimus‑induced ABCB1 downregulation in drug‑drug interactions

Yuko Nakayama et al. Biomed Rep. .

Abstract

Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor used in cancer chemotherapy and transplantation. Due to its therapeutic properties, everolimus has been used long-term in clinical practice. Drug interactions with everolimus during gastrointestinal absorption can alter the oral bioavailability of everolimus and/or concomitant drugs. However, the effects of everolimus on gastrointestinal absorption remain unknown. The present study assessed the impact of continuous exposure to everolimus on expression and function of the ATP-binding cassette (ABC) transporter ABCB1 and ABCG2 using a Caco-2 intestinal cell model. Caco-2 subline, Caco/EV, was established by continuously exposing Caco-2 cells to 1 µM everolimus. Cell viability was evaluated using WST-1 assay. mRNA levels were measured by reverse transcription-quantitative PCR. Transport activity of ABCB1 was evaluated through the cellular accumulation of Rhodamin 123, a substrate for ABCB1. The half-maximal inhibitory concentration (IC50) values for everolimus in Caco-2 and Caco/EV cells were 0.31 and 4.33 µM, respectively, indicating 14-fold resistance in Caco/EV cells. Sensitivity to paclitaxel and 7-ethyl-10-hydroxycamptothecin, which are substrates for ABCB1 and ABCG2, respectively, was enhanced in Caco/EV, but not in Caco-2 cells. The IC50 values of cisplatin were comparable in both cell lines. Furthermore, mRNA expression levels of ABCB1 and ABCG2 were lower in Caco/EV cells than in Caco-2 cells, and the cellular accumulation of Rhodamine 123 was significantly higher in Caco/EV cells. These findings demonstrated that continuous exposure to everolimus suppressed the expression and function of ABCB1 and ABCG2, suggesting potential drug-drug interactions via the suppression of ABCB1 and ABCG2 in the intestinal tract.

Keywords: ABCB1; Caco-2 cell; downregulation; drug interaction; everolimus; transporter.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Growth curves for Caco-2 and Caco/EV cells. n=24.
Figure 2
Figure 2
mRNA expression of ABCB1 and ABCG2 in Caco-2 and Caco/EV cells. n=3. **P<0.01 vs. Caco-2. ABC, ATP-binding cassette.
Figure 3
Figure 3
Rhodamine 123 accumulation in Caco-2 and Caco/EV cells. n=4. **P<0.01 vs. Caco-2. RFU, relative fluorescence unit.

Similar articles

References

    1. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 2006;12:273–286. doi: 10.2174/138161206775201965. - DOI - PubMed
    1. Dong J, Yuan L, Hu C, Cheng X, Qin JJ. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review. Pharmacol Ther. 2023;249(108488) doi: 10.1016/j.pharmthera.2023.108488. - DOI - PubMed
    1. To KKW, Huang Z, Zhang H, Ashby CR Jr, Fu L. Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy. Drug Resist Updat. 2024;73(101058) doi: 10.1016/j.drup.2024.101058. - DOI - PubMed
    1. Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al. Multidrug efflux transporter ABCG2: Expression and regulation. Cell Mol Life Sci. 2021;78:6887–6939. doi: 10.1007/s00018-021-03901-y. - DOI - PMC - PubMed
    1. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: Recent views. Biochem Pharmacol. 2002;64:943–948. doi: 10.1016/s0006-2952(02)01156-5. - DOI - PubMed

LinkOut - more resources